Here’s what you should know.
1. The prescription is used to treat gastroparesis in patients with type 1 and type 2 diabetes.
2. The trial evaluated the effects of relamorelin on key signs and symptoms of gastroparesis.
3. The trial was performed in a randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of dosing requirements.
4. Relamorelin was found to be safe and well-tolerated. There were some dose-related adverse events associated with it including the worsening of glycemic control in some patients.
5. Allergan will pay $200 million to Rhythm Holdings at the deal’s closing. Rhythm will also receive a contingent payment over the commercial sale of relamorelin.
More articles on GI/endoscopy:
Nonalcoholic fatty liver disease associated with $103B in annual medical costs: 3 study insights
https://www.beckersasc.com/gastroenterology-and-endoscopy/nonalcoholic-fatty-liver-disease-associated-with-103b-in-annual-medical-costs-3-study-insights.html
AGA launches patient education platform for IBD, pregnancy concerns: 3 notes
https://www.beckersasc.com/gastroenterology-and-endoscopy/aga-launches-patient-education-platform-for-ibd-pregnancy-concerns-3-notes.html
GI leader to know: Dr. R. David Shepard of Florida Medical Clinic
https://www.beckersasc.com/gastroenterology-and-endoscopy/gi-leader-to-know-dr-r-david-shepard-of-florida-medical-clinic.html
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.